Brief: Alzamend Neuro Announces Full Data Set From Phase Iia Multiple Ascending Dose Clinical Trial For Al001 Treatment Of Dementia Related To Alzheimer’S

Alzamend Neuro

16/10/2024 13:06

Oct 16 (Reuters) - Alzamend Neuro Inc  ALZN.O :
    * ALZAMEND NEURO ANNOUNCES FULL DATA SET FROM PHASE IIA
MULTIPLE
ASCENDING DOSE CLINICAL TRIAL FOR AL001 TREATMENT OF DEMENTIA
RELATED TO ALZHEIMER’S
    * ALZAMEND NEURO INC - IDENTIFIED DOSE UNLIKELY TO REQUIRE
LITHIUM
THERAPEUTIC DRUG MONITORING
    * ALZAMEND NEURO INC - MAXIMUM TOLERATED DOSE FOR AL001
CONFIRMED
AT 240 MG TID
    * ALZAMEND NEURO INC - TO INITIATE FIVE CLINICAL TRIALS
BASED ON
STUDY RESULTS

Source text for Eikon:  ID:nBw3S3hLza 
Further company coverage:  ALZN.O 

 ((Reuters.Briefs@thomsonreuters.com;))